PPT-Tenofovir Alafenamide (TAF)

in a SingleTablet Regimen in Initial HIV1 Therapy Combined Primary Results of Studies GSUS2920104 and GSUS2920111 David Wohl 1 Anton Pozniak 2 Melanie Thompson 3 Edwin DeJesus. An HIV pre-exposure prophylaxis trial in Thailand: . participant adherence and study results . National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of HIV/AIDS Prevention. A collaborative project involving: The Bangkok Metropolitan Administration, the. John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Albany Medical Center Hospital. NY/NJ AIDS Education and Training Center. When to Start. DHHS: Changing Criteria for Initiating ART. CD4+ Count, cells/mm. New Treatments for HIV. C. Ryan Tomlin, . Pharm.D. ., BCPS, AAHIVP. Mercy Health Saint Mary’s. Grand Rapids, Michigan. Outline. Newly Released Antiretroviral Medications. Isentress. HD. ® (. raltegravir. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 3rd Quarter. October-December 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Treatment-naïve Patients . Clinical Instructor, Harvard Medical School. Director of Research, CRI New England. Vice Chair, INSIGHT Scientific Steering Committee. Boston, USA . Calvin Cohen, MD, MSc. A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borkar. 1. ,M.Kulkarni. 1. ,M.Dravid. 3. 1. . Ruby hall clinic, Department of HIV Medicine, . Pune. , India. 2. Ruby hall clinic, Department of Nephrology, . of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. WITH AND WITHOUT COBICISTAT IN PREGNANCY . Jeremiah D. Momper. 1. , . Brookie. Best. 1. , . Jiajia. Wang. 2. , Alice Stek. 3. , Tim R. Cressey. 4. , Sandra Burchett. 5. , Regis Kreitchmann. 6. , David E. Shapiro. TOTEM. Switching the NRTI Backbone to Tenofovir DF-Emtricitabine. TOTEM: Study Design. Source. : . Valantin. MA, et al. . J . Antimicrob. . Chemother. . 2010;65:556-61.. TDF-FTC + Continue . 3. rd. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. Diese Präsentation dient ausschließlich der wissenschaftlichen Information gegenüber ärztlichen Fachkreisen. . Die Präsentation enthält keine werblichen Aussagen und dient nicht zu Werbezwecken. . FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg. Tenofovir. . Disoproxil. . Fumarate. to . Tenofovir. . Alafenamide. Have Improved Renal and Bone Safety through 48 Weeks. Study GS-US-292-0112. Samir K. Gupta. 1. , Anton Pozniak. 2. , Jose Arribas.